BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 13, 2024
See today's BioWorld
Home
» FDA Review of Gout Drug Sends Savient Stock Soaring
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA Review of Gout Drug Sends Savient Stock Soaring
June 15, 2009
By
Donna Young
No Comments
Shares of Savient Pharmaceuticals Inc. skyrocketed 56 percent Friday after FDA drug reviewers said in briefing documents that the firm's gout drug Krystexxa (pegloticase) was effective. (BioWorld Today)
BioWorld
